# Entyvio® (vedolizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vedolizumab

> The FDA approved Entyvio® (vedolizumab), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on April 18, 2024 for moderately to severely active Crohn's disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Entyvio® (vedolizumab) |
| Codes | MLN0002 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [moderately to severely active ulcerative colitis](https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis), [moderately to severely active crohn's disease](https://sec-api.dev/indications/moderately-to-severely-active-crohn-s-disease), [Pouchitis](https://sec-api.dev/indications/pouchitis), [Colitis, Ulcerative](https://sec-api.dev/indications/colitis-ulcerative), [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Crohn's Disease](https://sec-api.dev/indications/crohn-s-disease) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### December 17, 2019: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22761133_2024_Orig1s000OtherActionLtrs.pdf%22

### January 25, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125476 SUPPL-48 (Efficacy): submission_status AP, submission_status_date 20230125, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125476%22

### September 27, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761133 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230927, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761133%22

### April 18, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: moderately to severely active Crohn's disease.
- First seen 2025-05-28, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761359 ORIG-1 (Efficacy): submission_status AP, submission_status_date 20240418, review_priority STANDARD; sponsor_name TAKEDA PHARMS USA; product ENTYVIO (VEDOLIZUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761359%22
- Press release filed with the SEC (EX-99) (accession 0001395064-25-000063): "ENTYVIO / Generic name: vedolizumab - In April 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) approved ENTYVIO SC administration for maintenance therapy in adults with moderately to severely active Crohn's disease after induction therapy with ENTYVIO IV." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000063/a2025_convocation.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001628280-24-046860): "Based on initial Phase 1 clinical data, the company plans to initiate a Phase 2 platform trial in ulcerative colitis in mid-2025." https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/exhibit991-8xkdatarelease.htm

### May 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." https://clinicaltrials.gov/study/NCT04738942

### July 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." https://clinicaltrials.gov/study/NCT04779307

### February 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-02-05, last confirmed 2026-08-19.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-000641): "REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to Entyvio® (vedolizumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184326000641/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-003974): "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-057988): "In February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." https://www.sec.gov/Archives/edgar/data/1898416/000162828026057988/alvo-20260630.htm

### March 31, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-06-08, last confirmed 2026-06-08.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-003974): "Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®" https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_991.htm

### April 30, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." https://clinicaltrials.gov/study/NCT04779307?tab=results

### June 8, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: moderately to severely active ulcerative colitis.
- First seen 2026-06-08, last confirmed 2026-10-29.
- SEC Form 8-K (accession 0001395064-26-000345): "-In June 2026, Takeda announced that the U.S. Food and Drug Administration (FDA) accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease in pediatric patients ages 2 years and older." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000345/form6k-2_102926.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-003974): "REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration." https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-057988): "In June 2026, the FDA accepted for review the BLA for AVT16, the Company's proposed interchangeable biosimilar to Entyvio® (vedolizumab)." https://www.sec.gov/Archives/edgar/data/1898416/000162828026057988/alvo-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-003974): "On 8 June 2026, the Company announced that the FDA had accepted for review a BLA for" https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_993.htm
- SEC prospectus (424B) (accession 0000930413-26-001864): "Further, on June 8, 2026, we announced that our BLA for AVT16 has been accepted for review by the FDA." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "Further, on June 8, 2026, we announced that our BLA for AVT16 has been accepted for review by the FDA." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-26-005793): "AVT80 complements AVT16, Alvotech's proposed interchangeable biosimilar to Entyvio for intravenous administration for which the FDA accepted a BLA for review in May 2026." https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/exh_991.htm

### June 15, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04738942 (A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-15." https://clinicaltrials.gov/study/NCT04738942?tab=results

### 2H 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-08-04, last confirmed 2026-08-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331512): "Odyssey continues to expect the RIPK2 program to enter its next stage of clinical development, with initiation of a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab expected in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-ex99_1.htm

### August 31, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-08-31, last confirmed 2026-08-31.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-005793): "REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration." https://www.sec.gov/Archives/edgar/data/1898416/000117184326005793/exh_991.htm

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn's Disease.
- First seen 2025-01-17, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06227910 (A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06227910
- SEC prospectus (424B) (accession 0001193125-26-214819): "We currently expect to release topline combination induction results with vedolizumab from this trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526214819/odyssey__form_424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-161514): "We currently expect to release topline combination induction results with vedolizumab from this trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-20260417.htm
- SEC prospectus (424B) (accession 0001193125-26-214819): "Based on the efficacy and tolerability observed, we expect to commence a randomized, double-blind phase 2a trial assessing OD-001 in combination with an integrin-blocking therapy, vedolizumab, compared to vedolizumab plus placebo in the second half of 2026, with topline combination induction results expected in the second half of 2027 and OD-001 only 52-week maintenance results expected in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1882782/000119312526214819/odyssey__form_424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-161514): "Based on the efficacy and tolerability observed, we expect to commence a randomized, double-blind phase 2a trial assessing OD-001 in combination with an integrin-blocking therapy, vedolizumab, compared to vedolizumab plus placebo in the second half of 2026, with topline combination induction results expected in the second half of 2027 and OD-001 only 52-week maintenance results expected in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-20260417.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-331512): "OD-001 (RIPK2 scaffolding inhibitor): Initiate a Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both studies expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-274291): "Odyssey is continuing to advance OD-001 and expects to initiate both a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, with topline induction data from both trials expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526274291/odtx-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-214819): "Pending discussion with regulatory agencies, we expect to commence a randomized, double-blind phase 2a combination trial assessing OD-001 with an integrin-blocking therapy, vedolizumab, compared to vedolizumab plus placebo in the second half of 2026 and we expect to release topline induction results from this trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526214819/odyssey__form_424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-161514): "Pending discussion with regulatory agencies, we expect to commence a randomized, double-blind phase 2a combination trial assessing OD-001 with an integrin-blocking therapy, vedolizumab, compared to vedolizumab plus placebo in the second half of 2026 and we expect to release topline induction results from this trial in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312526161514/odtx-20260417.htm
- SEC registration statement (S-1) (accession 0001193125-25-008362): "We also expect to commence a second Phase 2a trial assessing OD-07656 in combination with the standard of care, integrin blocking therapy, vedolizumab in the first half of 2026 with topline combination induction results expected to be released in mid-2027." https://www.sec.gov/Archives/edgar/data/1882782/000119312525008362/d818486ds1.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06227910 (A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06227910

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pouchitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06443502 (A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-31 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06443502

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pouchitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06443502 (A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-31 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06443502

## Same indication

- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736) (ABBV)
- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [AZD7798](https://sec-api.dev/pdufa/azd7798) (AZN)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Darvadstrocel](https://sec-api.dev/pdufa/darvadstrocel) (TAK)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv) (ABBV)
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc) (ABBV)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) (JNJ)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vedolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Entyvio® (vedolizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vedolizumab

```bibtex
@misc{secapidev_pdufa_vedolizumab_20261116,
  title        = {Entyvio® (vedolizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vedolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vedolizumab_20261116","title":"Entyvio® (vedolizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vedolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
